NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $43.20.

NAMS has been the topic of several research analyst reports. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a “buy” rating and a $52.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Saturday. Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Citigroup lifted their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th.

NewAmsterdam Pharma Stock Performance

NAMS opened at $35.72 on Wednesday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $41.47. The company has a fifty day moving average of $28.94 and a two-hundred day moving average of $22.99. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -22.05 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to analysts’ expectations of $1.44 million. On average, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Buying and Selling

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,260 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average cost of $24.99 per share, for a total transaction of $31,487.40. Following the completion of the transaction, the director owned 3,027,864 shares of the company’s stock, valued at $75,666,321.36. The trade was a 0.04% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the completion of the transaction, the chief accounting officer owned 15,000 shares in the company, valued at $387,450. The trade was a 90.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 2,391 shares of company stock worth $58,424 and have sold 226,342 shares worth $5,748,019. 20.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NAMS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock valued at $80,000 after purchasing an additional 596 shares during the last quarter. Lisanti Capital Growth LLC raised its stake in shares of NewAmsterdam Pharma by 26.9% in the 1st quarter. Lisanti Capital Growth LLC now owns 49,110 shares of the company’s stock valued at $1,005,000 after acquiring an additional 10,395 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of NewAmsterdam Pharma by 12.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company’s stock valued at $451,000 after acquiring an additional 2,439 shares during the period. Alps Advisors Inc. raised its stake in shares of NewAmsterdam Pharma by 4.4% in the 1st quarter. Alps Advisors Inc. now owns 77,961 shares of the company’s stock valued at $1,596,000 after acquiring an additional 3,252 shares during the period. Finally, Arizona State Retirement System purchased a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at approximately $215,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.